Praxis Precision Medicine is a biotechnology business based in the US. Praxis Precision Medicine shares (PRAX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $64.94 – an increase of 12.86% over the previous week. Praxis Precision Medicine employs 82 staff and has a trailing 12-month revenue of around $1.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $64.94 |
|---|---|
| 52-week range | $13.01 - $67.21 |
| 50-day moving average | $55.82 |
| 200-day moving average | $47.00 |
| Wall St. target price | $146.44 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-5.59 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $64.94 from 2024-10-04
| 1 week (2024-10-01) | 13.08% |
|---|---|
| 1 month (2024-09-06) | 20.21% |
| 3 months (2024-07-08) | 53.23% |
| 6 months (2024-04-08) | 20.95% |
| 1 year (2023-10-06) | 4,144.44% |
|---|---|
| 2 years (2022-10-07) | 2,851.82% |
| 3 years (2021-10-08) | 227.65% |
| 5 years (2019-10-04) | N/A |
| Revenue TTM | $1.8 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -28.87% |
| Return on equity TTM | -47.16% |
| Profit margin | 0% |
| Book value | $23.60 |
| Market Capitalization | $1 billion |
TTM: trailing 12 months
Praxis Precision Medicine's shares were split on a 1:15 basis on 28 November 2023. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Praxis Precision Medicine shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Praxis Precision Medicine shares which in turn could have impacted Praxis Precision Medicine's share price.
Over the last 12 months, Praxis Precision Medicine's shares have ranged in value from as little as $13.005 up to $67.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Praxis Precision Medicine's is 2.741. This would suggest that Praxis Precision Medicine's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Praxis Precision Medicine's beta into context you can compare it against those of similar companies.
Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc. ; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc. ; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.